Researchers at Johnson & Johnson and Danish partner Bavarian Nordic have developed a potential vaccine against the Ebola virus.
An Ebola vaccine has proved successful in a large-scale human trial led by the World Health Organization.
Congress should reconvene, work together across the aisle and push through a funding package compromise now, says Dr. Judith Monroe.
Critical Zika funding legislation is one step (and about four Senate votes) away from the president's desk, says Martha Roby. We need to pass it now.
Zika virus is a growing threat, but funding is severely lacking. Here's what the private sector can do, say Dikembe Mutombo and Gary Cohen.
Zika shouldn't have caught us by surprise, writes Dr. Claire Pomeroy. Here's what needs to be done to prevent the next killer virus.
A Scottish nurse who recovered from Ebola has been readmitted to the hospital for a third time.
The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.
Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.
A Scottish nurse who contracted the Ebola virus in Sierra Leone last year is back in hospital for more treatment.
Teen creates cheaper way to test for Ebola
Olivia Hallisey, Grand Prize Winner, Google Science Fair, 2015, talks about her creation of a portable, low-cost diagnostic test for Ebola and other infectious diseases.
The details of a very promising Ebola vaccine, with CNBC's Meg Tirrell.
A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?
An experimental Ebola vaccine is showing early promise in Africa, and Beijing has been chosen to host the 2022 Winter Olympic Games, reports CNBC's Sue Herera.
An Ebola vaccine developed in record time has proved highly effective against the deadly virus in a large trial in Guinea.
Ebola briefly returned to the headlines this week with a scare at a hospital in New York, but the deadly virus continues to claim victims in West Africa.
As the world focuses on Ebola, CNBC takes a look at some of the worst epidemics throughout the ages.
Dr. Kent Brantly, Ebola survivor and "Called for Life" co-author, and Amber Brantly "Called for Life" co-author, recount Kent's battle with the Ebola virus.
Novavax shares rose at Tuesday's market open after the bio-pharmaceutical firm said its Ebola vaccine showed promising early results.